Cardiovascular Revascularization Medicine最新文献

{"title":"Venoarterial extracorporeal membrane oxygenation with and without left ventricular unloading in patients with cardiac arrest: A nationwide analysis from the United States.","authors":"Abdilahi A Mohamoud, Adnan Khalif, Nadhem Abdallah, Mahmoud Ismayl, Abdirahman Wardhere, Andrew M Goldsweig","doi":"10.1016/j.carrev.2025.09.004","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.09.004","url":null,"abstract":"<p><strong>Background: </strong>Extracorporeal cardiopulmonary resuscitation (ECPR) using veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is a promising strategy for refractory cardiac arrest. However, the role of left ventricular (LV) unloading during ECPR remains uncertain.</p><p><strong>Methods: </strong>We queried the United States National Inpatient Sample (2016-2021) to identify adult patients with out-of-hospital (OHCA) and in-hospital cardiac arrest (IHCA) who received ECPR. Patients were stratified based on the use of either VA-ECMO only or VA-ECMO with intra-aortic balloon pump (IABP) or VA-ECMO with Impella (ECPELLA) for ventricular unloading. Multivariable logistic regression was used to compare in-hospital outcomes between the groups.</p><p><strong>Results: </strong>Among 6915 patients receiving ECPR, VA-ECMO alone was used in 5147 (74.4 %), VA-ECMO-IABP in 811 (11.7 %), and ECPELLA in 957 (13.9 %). In IHCA patients, ECPELLA was associated with 50 % lower odds of in-hospital mortality compared to VA-ECMO alone (adjusted odds ratio [aOR] 0.50, 95 % CI 0.31-0.81, p < 0.01). No significant difference was found in OHCA patients. VA-ECMO-IABP was not associated with a mortality benefit vs. VA-ECMO alone in either OHCA or IHCA.</p><p><strong>Conclusion: </strong>LV mechanical unloading with ECPELLA was associated with improved survival in IHCA patients but not in OHCA patients compared to VA-ECMO alone. The addition of an IABP to VA-ECMO was not associated with a mortality benefit.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145092733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A pharmacokinetic comparison between three drug delivery devices in porcine coronary arteries.","authors":"Takamasa Tanaka, Rika Kawakami, Tatsuya Shiraki, Takafumi Nakayama, Kazuhiro Fujiyoshi, Tomoyo Hamana, Yusuke Adachi, Atsushi Sakamoto, Alyssa Grogan, Renu Virmani, Aloke V Finn","doi":"10.1016/j.carrev.2025.09.001","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.09.001","url":null,"abstract":"<p><strong>Background: </strong>Catheter-based drug delivery systems have evolved in percutaneous coronary interventions (PCI). Drug-coated balloons (DCBs) deliver agents to obstructive atherosclerotic lesions without permanent implants, but their pharmacokinetic profiles vary and may affect efficacy and safety.</p><p><strong>Method: </strong>Twenty-seven Yucatan Miniature Swine underwent treatment with SEL-SEB (SELUTION SLR™), MT-SCB (MagicTouch™), or EES (XIENCE™) in the right coronary or left circumflex arteries. Drug levels were measured in treated arteries and downstream myocardium at 7, 60, and 90 days. MT-SCB samples were extracted with ZnSO₄/methanol, whereas SEL-SEB samples underwent two-step extraction (ZnSO₄/methanol followed by acetonitrile/acetone).</p><p><strong>Result: </strong>A total of 54 arteries underwent pharmacokinetic evaluation (n = 6 treated arteries per time point) from 27 swine. At 7 days, the mean of arterial drug levels was 1767.5 ng/g for SEL-SEB, 1136.5 ng/g for MT-SCB, and 1057.4 ng/g for EES (p = 0.94). By 60 days, SEL-SEB and EES maintained high levels (1146.3 and 837.3 ng/g), while MT-SCB fell sharply to 5.8 ng/g (p < 0.05). At 90 days, SEL-SEB and EES remained stable (360.7 ng/g and 916.5 ng/g, respectively), although MT-SCB was negligible, 2.0 ng/g (p < 0.05). Drug levels in the downstream myocardium at 7 days were lowest with EES (0.1 ng/g), higher with SEL-SEB (11.3 ng/g), and highest with MT-SCB (281.5 ng/g) (p < 0.05).</p><p><strong>Conclusions: </strong>SEL-SEB shows sustained arterial drug retention, more closely resembling the gold-standard EES. This data suggests that SEL-SEB should produce durable outcomes without the need for a permanent implant.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145066154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Functional outcomes of clip use in severe mitral regurgitation and shock (FOCUS-MR): Single-center registry.","authors":"Mustafa Suppah, Sant Kumar, Pallavi Bellamkonda, Said Alsidawi, Beeletsega Yeneneh, Ambar Andrade, Travis A Warner, Kevin Brady, Hursh Naik","doi":"10.1016/j.carrev.2025.09.002","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.09.002","url":null,"abstract":"<p><strong>Background: </strong>Severe mitral regurgitation (MR) is associated with significant morbidity and mortality, particularly in patients with shock. While surgical repair remains the standard of care in acute primary MR, many critically ill patients are ineligible due to advanced age or comorbidities. Transcatheter edge-to-edge mitral valve repair (TEER) with MitraClip has emerged as a promising alternative. Unlike prior registries, this study directly compares cardiogenic vs. mixed shock using invasive criteria, integrates SCAI staging, BOS-MA2 risk prediction, and valve phenotyping, and highlights the need for prospective studies to refine patient selection.</p><p><strong>Objectives: </strong>To evaluate the feasibility, safety, and clinical outcomes of MitraClip implantation in patients with severe MR and cardiogenic or mixed shock.</p><p><strong>Methods: </strong>This retrospective cohort study analyzed 47 patients with severe MR and cardiogenic (n = 32) or mixed shock (n = 15) treated with MitraClip between January 2017 and December 2023. Procedural success, defined as successful clip deployment, reduction of MR to ≤2, and absence of major device-related complications, was assessed alongside short- and long-term outcomes. Baseline characteristics, hemodynamic parameters, and outcomes were compared between shock subtypes.</p><p><strong>Results: </strong>Procedural success was achieved in 100 % of cases. MR severity improved significantly from grade 4 to grade ≤ 2 (p < 0.001). In-hospital mortality was 8.5 %, and 1-year mortality was 25.5 %. Patients with mixed shock had higher in-hospital mortality (20 % vs. 3.1 %, p = 0.53) and lower 1-year readmission rates (21.4 % vs. 58.6 %, p = 0.02). Predictors of 1-year mortality included advanced age, elevated left atrial volume index, and prolonged vasopressor use.</p><p><strong>Conclusions: </strong>MitraClip implantation is a feasible intervention for severe MR in patients with shock, demonstrating high procedural success and meaningful reductions in MR severity across both cardiogenic and mixed shock. These exploratory findings highlight the need for larger prospective studies to validate outcomes and refine patient selection.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145056142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bayesian insights into fractional flow reserve-guided complete revascularization versus culprit-only percutaneous coronary intervention in patients with myocardial infarction.","authors":"Lucas M Barbosa, Vinícius Martins Rodrigues Oliveira, Lara Guedes, Jhonattan Rodrigues Garcia Costa, Robert Alcântara","doi":"10.1016/j.carrev.2025.08.020","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.08.020","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Declining myocardial infarction mortality in young and middle-aged Americans and impact of COVID-19 pandemic.","authors":"Ali Bin Abdul Jabbar, Mahmoud Ismayl, Mason Klisares, John Osborne, Mohamed Azouz, Hyo Jung Tak, Ahmed Aboeata, Amjad Kabach, Andrew M Goldsweig","doi":"10.1016/j.carrev.2025.08.021","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.08.021","url":null,"abstract":"<p><strong>Background: </strong>Acute myocardial infarction (AMI) is a leading cause of cardiovascular disease (CVD) mortality among young and middle-aged individuals in the United States (US). Though AMI mortality overall has been decreasing in the US, contemporary trends in AMI-related mortality in the young and middle-aged population and the impact of the COVID-19 pandemic on these trends are unknown.</p><p><strong>Methods: </strong>The Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) database was used to analyze death certificates from 1999 to 2023 for AMI-related deaths among the US population aged 25-64. Age-adjusted mortality rates (AAMRs) per 100,000 people and associated annual percent changes (APCs) were calculated using Joinpoint regression analysis. Mortality trends were stratified by sex, race/ethnicity, census region, and state for comparative analysis.</p><p><strong>Results: </strong>From 1999 to 2023, there were 970,454 AMI-related deaths among U.S. adults aged 25-64 years. The annual number of AMI-related deaths decreased from 44,040 in 1999 to 31,522 in 2023. The overall AAMR per 100,000 decreased from 31.02 deaths (95 % confidence interval [CI] 30.73-31.31) in 1999 to 15.29 (95 % CI 15.11-15.46) in 2023 (average APC -2.92 %, 95 % CI -3.22 to -2.75). The AAMR per 100,000 declined at a faster rate from 31.02 in 1999 to 19.57 in 2010 (1999-2010, APC -4.26), followed by a slower rate from 19.57 in 2010 to 16.67 in 2019 (2010-2019, APC -1.41). The declining trend was disrupted by a transient increase during the COVID-19 pandemic, with a peak AAMR of 19.73 (95 % CI, 19.53 to 19.93) in 2021 (2019-2021, APC 8.52). The declining trend resumed from 2021 to 2023, with AAMR decreasing to its lowest levels of 15.29 in 2023 (2021-2023, APC -12.58). Heterogeneity across demographic and regional groups narrowed during these 25 years. However, disparities are still prevalent, with men, non-Hispanic (NH) Black or African American, American Indian or Alaska Native, and residents of the Southern United States having higher mortality rates.</p><p><strong>Conclusion: </strong>AMI-related mortality declined significantly from 1999 through 2023 in the young and middle-aged population of the US. AMI-related mortality rates increased transiently during the COVID-19 pandemic, but the declining trend resumed in 2022. Differences across demographic and regional subgroups narrowed; however, disparities remain prevalent and require comprehensive efforts to improve cardiovascular health, outcomes, and health equity among the young and middle-aged populations of the US.</p>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145066166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"A stratified pathway to stent-free reperfusion: Selecting suitable patients in ST-elevation myocardial infarction\": The authors reply.","authors":"Rafael Mila, Juan Albistur, Victor Dayan","doi":"10.1016/j.carrev.2025.08.016","DOIUrl":"https://doi.org/10.1016/j.carrev.2025.08.016","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145082102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in surgical and transcatheter interventions for tricuspid regurgitation: A national inpatient sample analysis from 2011 to 2020","authors":"Pedro Villablanca ,&nbsp;Ahmad Jabri ,&nbsp;Laith Alhuneafat ,&nbsp;Anand Maligireddy ,&nbsp;Waqas Rasheed ,&nbsp;Kyle Kapcin ,&nbsp;Katie Manalo ,&nbsp;Azeem Latib ,&nbsp;Gennaro Giustino ,&nbsp;Raef Fadel ,&nbsp;Ahmad Al Abdouh ,&nbsp;Mohammed Mhanna ,&nbsp;Nicholas Amoroso ,&nbsp;Dee Dee Wang ,&nbsp;Brian O'Neill ,&nbsp;Rodrigo Bagur ,&nbsp;Luai Madanat ,&nbsp;Brian Renard ,&nbsp;Vikas Aggarwal ,&nbsp;Mohammad Alqarqaz ,&nbsp;William W. O'Neill","doi":"10.1016/j.carrev.2024.11.005","DOIUrl":"10.1016/j.carrev.2024.11.005","url":null,"abstract":"<div><h3>Background</h3><div><span>Tricuspid regurgitation (TR) poses a significant health burden, with severe disease linked to poor long-term outcomes, including intractable </span>right heart failure. Despite guidelines advocating intervention, surgical options have historically been limited due to high mortality rates. Advancements in transcatheter valve interventions (TTVI) have renewed interest in less invasive treatments.</div></div><div><h3>Methods</h3><div><span>Utilizing data from the National Inpatient Sample (NIS) spanning 2011 to 2020, this study analyzed trends, factors influencing procedure selection, and outcomes of surgical and transcatheter tricuspid valve interventions across the United States. The analysis included 98,202 interventions, examining demographic and clinical disparities among patients undergoing TTVI, surgical </span>tricuspid valve repair<span> (STVr), and surgical tricuspid valve replacement (STVR).</span></div></div><div><h3>Results</h3><div>Between 2011 and 2020, 98,202 TV interventions were analyzed. Over time, total TV interventions increased, with TTVI peaking in 2020 (4.8 %). STVr declined from 78.20 % (2011) to 76.80 % (2020), while STVR decreased from 21.80 % to 18.40 %. Factors influencing procedure selection included age, race, hospital size, teaching status, and comorbidities. STVR accounted for the highest proportion of TV procedure-related deaths, followed by STVr and TTVI. STVR-related deaths declined over time, while STVr-related deaths increased.</div></div><div><h3>Conclusion</h3><div>This study provides a helpful visual representation of mortality trends and can inform healthcare professionals about the changing landscape of TV procedure outcomes. Further analysis would be necessary to understand the underlying causes of these trends, such as changes in patient demographics, procedural volume, technology, and clinical practices over time.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"78 ","pages":"Pages 97-103"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142644960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to treat pulmonary embolism – A question worth consideration","authors":"Spencer B. King III","doi":"10.1016/j.carrev.2025.08.010","DOIUrl":"10.1016/j.carrev.2025.08.010","url":null,"abstract":"","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"78 ","pages":"Pages 120-121"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144974191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous coronary intervention for stable late ST-elevation myocardial infarction with symptoms onset between 12 and 72 h – A systematic review","authors":"Shumail Fatima ,&nbsp;Matthew E. Harinstein ,&nbsp;Mubashir Hussain ,&nbsp;John J. Pacella","doi":"10.1016/j.carrev.2024.12.014","DOIUrl":"10.1016/j.carrev.2024.12.014","url":null,"abstract":"<div><h3>Background</h3><div>There exists clinical equipoise regarding whether and when an invasive approach should be preferred over conservative treatment in the management of stable late ST-elevation myocardial infarction (STEMI) presenting within 12 to 72 h of symptom onset.</div></div><div><h3>Objective</h3><div>To perform a systematic review to identify the most effective treatment strategy between percutaneous coronary intervention (PCI) and medical therapy in stable late STEMI presenters by comparing their respective outcomes as well as determine the optimal timing of PCI by evaluating the outcomes of urgent versus non-urgent PCI approach in this patient population.</div></div><div><h3>Methods</h3><div>PubMed, Embase, and Cochrane databases were queried from inception until March 2024 for studies comparing the outcomes of PCI versus medical therapy, as well as urgent versus non-urgent PCI, in stable late STEMI patients presenting with symptom onset within 12–72 h. Quality of the studies and risk of bias were assessed using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) criteria and the Cochrane Risk of Bias (ROBINS-I 2016) tool, respectively.</div></div><div><h3>Results</h3><div><span>A total of 8 studies were included in this systematic review that met the inclusion criteria. Among these, 5 studies (1 randomized controlled trial (RCT), 1 post-hoc analysis, and 3 observational studies) with an aggregate of 3820 participants compared PCI and medical therapy in stable late STEMI presenters. They found that PCI was associated with statistically significant better short- and long-term outcomes by lowering all-cause mortality, recurrent myocardial infarction (MI), and infarct size, and by improving myocardial salvage index (</span><em>P</em><span> &lt; 0.001). Similarly, a non-statistically significant improvement was seen in the events of cardiac death, heart failure, and revascularization as well as ejection fraction percentage with PCI (</span><em>P</em> &gt; 0.05). The other 3 studies, involving 1270 participants, were observational and compared urgent versus non-urgent PCI and did not find any statistically significant difference in clinical outcomes between the two approaches (<em>P</em> &gt; 0.05). The included studies were significantly heterogeneous in methodologies, follow-up intervals, and reporting of outcomes. Most of the studies provided moderate quality of evidence and had moderate to serious risk of bias.</div></div><div><h3>Conclusions and relevance</h3><div>Revascularization through PCI is associated with superior short- and long-term outcomes compared to medical therapy in stable late STEMI patients presenting within 12–72 h of symptom onset. However, the optimal timing of PCI needs further investigation.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"78 ","pages":"Pages 1-9"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142956729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"SoutheAsTern eUrope microciRculATION (SATURATION) registry - Design and rationale","authors":"Natalija Odanovic ,&nbsp;Konstantinos Tsioufis ,&nbsp;Kyriakos Dimitriadis ,&nbsp;Athanasios Sakalidis ,&nbsp;Michail I. Papafaklis ,&nbsp;Periklis Davlouros ,&nbsp;Igor Ivanov ,&nbsp;Milenko Cankovic ,&nbsp;Andreas S. Kalogeropoulos ,&nbsp;Michalis Hamilos ,&nbsp;Emmanuel Sideras ,&nbsp;Maayan Konigstein ,&nbsp;Lior Zornitzki ,&nbsp;Tomas Kovarnik ,&nbsp;Zoltan Ruzsa ,&nbsp;Zsolt Piroth ,&nbsp;Marija Zdravkovic ,&nbsp;Zlatko Mehmedbegovic ,&nbsp;Zoran Miovski ,&nbsp;Hrvoje Jurin ,&nbsp;Ivan Ilic","doi":"10.1016/j.carrev.2024.11.012","DOIUrl":"10.1016/j.carrev.2024.11.012","url":null,"abstract":"<div><h3>Background</h3><div>A considerable number of symptomatic patients leave the cardiac catheterization lab without a definitive diagnosis for their symptoms because no epicardial stenoses are found. The significance of disorders of coronary microvasculature and vasomotion as the cause of symptoms and signs of ischemia has only recently been appreciated. Today we have a wide spectrum of invasive coronary physiology tools but little is known about when and how these tools are used in clinical practice.</div></div><div><h3>Study design and methodology</h3><div>SoutheAsTern eUrope microciRculATION (SATURATION) registry will study the regional practice of patient selection for coronary function testing, indications, non-invasive ischemia testing, medications, procedural aspects of invasive physiology evaluation, and treatment changes after testing. The registry is expected to include 1600 patients in participating centers in Southeastern Europe from 2024 to 2029, using the thermodilution technique for evaluation of microcirculation. Major adverse cardiovascular events as well as patient-centered outcomes such as burden of angina and quality of life using Seattle Angina Questionnaire (SAQ) and EQ-5D-5L will be recorded. The study will include patients with different stages of coronary artery disease (presence of disease or degree of stenosis) to elucidate the effect of coronary microcirculation on the outcomes in this broad group.</div></div><div><h3>Conclusion</h3><div>The registry will provide information regarding the current practice of invasive coronary physiology assessment in populations at high cardiovascular risk in Southeastern Europe. This could lead to a better understanding of coronary microvascular dysfunction and its relationship to various degrees of coronary atherosclerosis together with potential interventions that can be beneficial.</div></div>","PeriodicalId":47657,"journal":{"name":"Cardiovascular Revascularization Medicine","volume":"78 ","pages":"Pages 104-107"},"PeriodicalIF":1.9,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142822775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}